What is essential tremor?
Essential tremor is a common, progressive neurological disorder characterized by involuntary, rhythmic shaking—most frequently affecting the hands and arms, but potentially involving the head, voice, trunk, or legs. It is classified as a movement disorder and is distinct from Parkinson disease, as it typically occurs during voluntary movement (action tremor) rather than at rest. The tremor often worsens with stress, fatigue, caffeine, or purposeful activity—such as holding a cup or writing—and may improve with alcohol consumption in some individuals, though this is not recommended as a treatment strategy.
The underlying pathophysiology involves abnormal oscillatory activity within the cerebello-thalamo-cortical circuit, with evidence pointing to dysfunction in the cerebellum and its connections to the thalamus and motor cortex. While the exact cause remains unknown—hence the term “essential”—genetic factors play a significant role: approximately 50–70% of cases are familial, often inherited in an autosomal dominant pattern, with several candidate genes identified (e.g., *FUS*, *STK32B*, *PPARGC1A*). However, no single gene accounts for most cases, suggesting genetic heterogeneity and likely contributions from environmental modifiers.
Clinically, essential tremor usually begins insidiously in adulthood—often after age 40—but can manifest at any age, including childhood. Diagnosis is primarily clinical, based on history and neurological examination; neuroimaging and laboratory tests are used only to exclude secondary causes such as hyperthyroidism, metabolic disturbances, medication-induced tremor (e.g., SSRIs, valproate), or structural brain lesions. Prognosis is generally favorable in terms of life expectancy, but functional impairment can increase over time, particularly with worsening upper-limb tremor that interferes with activities of daily living, handwriting, or social participation.
Management is individualized and symptom-driven. First-line pharmacotherapy includes propranolol (a nonselective beta-blocker) and primidone (an antiseizure medication); both demonstrate moderate efficacy in reducing tremor amplitude. Second-line options include gabapentin, topiramate, or alprazolam—though benzodiazepines carry risks of dependence and cognitive side effects. For severe, medication-refractory cases, deep brain stimulation (DBS) targeting the ventral intermediate nucleus (VIM) of the thalamus is an established, highly effective surgical intervention. Emerging therapies, including focused ultrasound thalamotomy, offer noninvasive alternatives with promising outcomes.